Halted trial tests new injection for rare metabolic disorder
Disease control
Terminated
This study aimed to test the safety and drug levels of an experimental medicine called ARCT-810 in people aged 12 and older with a rare genetic condition called ornithine transcarbamylase (OTC) deficiency. Participants received either the drug or a placebo via intravenous injecti…
Phase: PHASE2 • Sponsor: Arcturus Therapeutics, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC